Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Takes $3.59 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Posted by Defense World Staff on Aug 13th, 2023

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 16,010 shares of the biotechnology company’s stock, valued at approximately $3,586,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Global Retirement Partners LLC boosted its position in shares of United Therapeutics by 198.7% during the first quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company’s stock worth $49,000 after buying an additional 149 shares during the period. Assetmark Inc. lifted its position in United Therapeutics by 12.5% in the first quarter. Assetmark Inc. now owns 270,423 shares of the biotechnology company’s stock worth $60,564,000 after purchasing an additional 30,060 shares during the period. John G Ullman & Associates Inc. acquired a new stake in United Therapeutics in the first quarter worth approximately $1,887,000. Watershed Asset Management L.L.C. lifted its position in United Therapeutics by 13.8% in the first quarter. Watershed Asset Management L.L.C. now owns 1,122 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 136 shares during the period. Finally, MQS Management LLC acquired a new stake in United Therapeutics in the first quarter worth approximately $228,000. 95.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on UTHR shares. LADENBURG THALM/SH SH upped their target price on United Therapeutics from $256.00 to $268.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Morgan Stanley upped their target price on United Therapeutics from $316.00 to $318.00 and gave the stock an “overweight” rating in a research report on Thursday, August 3rd. HC Wainwright restated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, August 3rd. Argus cut their price objective on United Therapeutics from $300.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, April 21st. Finally, Wedbush increased their price objective on United Therapeutics from $305.00 to $307.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $296.44.

Read Our Latest Analysis on United Therapeutics

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $236.25, for a total value of $1,417,500.00. Following the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,646,513.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $236.25, for a total value of $1,417,500.00. Following the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,646,513.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 2,500 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $243.87, for a total transaction of $609,675.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $8,925,398.13. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,500 shares of company stock valued at $7,227,075. 12.50% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $237.80 on Friday. The company’s fifty day moving average is $230.13 and its two-hundred day moving average is $230.76. The company has a quick ratio of 8.40, a current ratio of 8.68 and a debt-to-equity ratio of 0.15. United Therapeutics Co. has a 12-month low of $201.65 and a 12-month high of $283.09. The company has a market cap of $11.16 billion, a P/E ratio of 13.45 and a beta of 0.61.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported $5.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.57 by $0.67. United Therapeutics had a net margin of 41.29% and a return on equity of 17.52%. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $524.18 million. During the same period in the previous year, the business earned $2.41 EPS. The company’s revenue was up 27.8% on a year-over-year basis. Equities analysts expect that United Therapeutics Co. will post 18.8 earnings per share for the current fiscal year.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.